277 filings
Page 9 of 14
8-K
tr1 1dw80lmw
17 Jul 20
Entry into a Material Definitive Agreement
5:19pm
8-K
6m7uhcrx4p2fik nbxg
15 Jul 20
Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate
7:30am
8-K
jtt7t7yj
2 Jul 20
Moleculin Provides Update on Annamycin Clinical Development
7:32am
8-K
gyt1clk5j2obxsa
1 Jul 20
New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model
7:31am
8-K
yfuot7 m388rti5z3x
25 Jun 20
Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases
7:31am
8-K
svlpydm5urr0i 40i88w
17 Jun 20
Departure of Directors or Certain Officers
4:20pm
8-K
iuimk 7kuvvx1
16 Jun 20
Moleculin Announces Confirmatory In Vitro Analysis of WP1122
7:32am
8-K
ky2u jmev
28 May 20
Moleculin Announces Common Stock
7:30am
8-K
r36dwy
27 May 20
Moleculin Provides Update on Coronavirus Drug Development
5:20pm
8-K
5smkkvz iirk
18 May 20
Moleculin Announces Nasdaq Trading Halt Pending Receipt of Additional Information
4:01pm
8-K
1coig25poze6dba7p
11 May 20
Regulation FD Disclosure
7:31am
8-K
x7f0l3m glpewy
23 Apr 20
Other Events
4:06pm
8-K
riqanmpwg f3
22 Apr 20
Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team
7:30am
8-K
uys9 lp0rxe0f
17 Apr 20
Regulation FD Disclosure
4:04pm
8-K
m14k30j80j22aq7la
15 Apr 20
Moleculin Announces Leading Virologist Joins Development Team
7:30am
8-K
2k7ae2ok3kwylz 3xaa0
14 Apr 20
Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate
7:30am
8-K
0wwvlso9c494adde8v
8 Apr 20
Other Events
7:30am
8-K
n0uk6io787d61nq vl1r
2 Apr 20
Moleculin Announces Additional Positive Safety Data in EU AML Trial
7:30am
8-K
cbqq04bgg1tvas 32e
26 Mar 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
8-K
lpelkklduq09pnwd6bc
19 Mar 20
Results of Operations and Financial Condition
4:16pm